StockTake: $3M for Euro market push

Bioxyne’s (ASX:BXN) latest $3 million capital raise has gained piqued interest from new and existing institutional investors globally.

The over subscribed raise will fill the company’s coffers, enabling it to build medical cannabis manufacturing facilities across key European markets.

Watch the video for the latest.

 

This video was developed in collaboration with Bioxyne, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Related Topics

Explore more

Explore more

Investor Guide: Health & Biotech FY2025 featuring Tim Boreham

Read The Guide